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Helminth-derived excretory/secretory (ES) products have been demonstrated to mediate 
the anti-inflammatory/regulatory environment associated with helminth infection (for a 
review see Allen et al. 2011). The ES products of helminths have been exploited for 
therapeutic benefit in both murine and human models of autoimmune diseases (Zaccone 
et al. 2003; Zheng et al. 2008; Motomura et al. 2009; Ruyssers et al. 2009; Johnston et 
al. 2010; Cancado et al. 2011; Carranza et al. 2012; Kuijk et al. 2012). In our 
laboratory, the ES products of the liver fluke trematode, Fasciola hepatica, have been 
shown to prevent autoimmune type 1 diabetes in a murine model (Lund et al. in 
preparation). Disease prevention was associated with the initiation and perpetuation of 
anti-inflammatory/regulatory immune responses, including the generation of 
alternatively activated macrophages, regulatory T cells and regulatory B cell 
populations (Lund et al. in preparation). Nevertheless, the individual molecular 
components within the ES responsible for these phenomenon are unknown. Therefore, 
HPLC fractionation of the ES products of Fasciola hepatica was undertaken. This 
revealed a number of components with immune-modulatory effects. One of these 
Fasciola hepatica products is a cysteine protease, cathepsin L1 (FhCL1), and in fact it 
comprises a large proportion of the total ES products. In mice, FhCL1 suppresses pro-
inflammatory immune responses through cleavage of toll-like receptor (TLR)-3, 
resulting in modulation of cell signalling in peritoneal macrophages (Donnelly et al. 
2010). 
 
This thesis therefore examines the effect of FhCL1 in human monocyte-derived 
macrophages. FhCL1 was shown to enhance expression of pro-inflammatory cytokines 
IL-6 and IL-8 in response to lipopolysaccharide. This was associated with the up-
regulation of surface CD14, and the activation of TLR4 cell signalling via both the 
myeloid differentiation primary response gene 88 (MyD88)-dependent and toll-
interleukin-1 receptor-domain-containing adaptor-inducing interferon-E (TRIF)-
dependent signalling pathways. Furthermore, expression of IL-10 and co-stimulatory 
molecule CD86 was down-regulated in FhCL1-treated human monocyte-derived 
macrophages, and this was attributed to suppression of late endosomal TRIF-dependent 
signalling, with down-regulation of TRAF3. Although, FhCL1 modulated TLR 
xvi 
 
signalling in human and murine macrophages, and suppressed TRIF-dependent 
signalling in both human and mouse macrophages, FhCL1 enhanced pro-inflammatory 
cytokine expression in human monocyte-derived macrophages. Therefore, FhCL1 
modulates immune responses in human monocyte-derived macrophages, albeit 
differently from murine peritoneal macrophages. Furthermore, while FhCL1 degraded 
TLR3 in murine peritoneal macrophages, FhCL1 had no effect on TLR3 or TLR4 
expression or localisation in human monocyte-derived macrophages. However, 
treatment with FhCL1 was shown to suppress the uptake of lipopolysaccharide (LPS) 
by human macrophages, which appeared to correlate with altered D-tubulin localisation. 
Thus suppressed uptake of LPS correlates with the suppression of TRIF-dependent late 
endosomal signalling. 
 
Nanotubes are cellular protrusions which connect cells and are utilised for the transport 
of cellular components between cells (reviewed in Gerdes et al. 2008; and Gurke et al. 
2008). An incidental finding of this study was the observation of nanotubes connecting 
monocyte-derived macrophages in culture, and the documented trafficking of TLR4 
between human macrophages, through these nanotubes. Interestingly, LPS stimulation 
enhanced the movement of TLR4 into nanotubes, but this was partially suppressed by 
FhCL1. 
 
Taken together, the work presented in this thesis provides insight into the mechanism of 
action of FhCL1 in human monocyte-derived macrophages. Investigating the immune-
modulatory effects of individual helminth-derived molecules is an important step in 
understanding the mechanisms by which helminths modulate host immune responses. 
Ultimately, such products may be harnessed as potential therapeutic agents in various 
situations, depending on their effect on the immune system. 
 
